EW vs. BSX, SYK, MDT, BDX, IDXX, RMD, DXCM, STE, PODD, and HOLX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), and Hologic (HOLX). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences vs.
Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences presently has a consensus target price of $78.48, suggesting a potential upside of 12.48%. Boston Scientific has a consensus target price of $97.26, suggesting a potential downside of 1.49%. Given Edwards Lifesciences' higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Boston Scientific.
Edwards Lifesciences has a net margin of 70.82% compared to Boston Scientific's net margin of 11.26%. Edwards Lifesciences' return on equity of 20.76% beat Boston Scientific's return on equity.
Edwards Lifesciences received 290 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 71.00% of users gave Edwards Lifesciences an outperform vote while only 69.69% of users gave Boston Scientific an outperform vote.
In the previous week, Boston Scientific had 8 more articles in the media than Edwards Lifesciences. MarketBeat recorded 28 mentions for Boston Scientific and 20 mentions for Edwards Lifesciences. Boston Scientific's average media sentiment score of 0.89 beat Edwards Lifesciences' score of 0.66 indicating that Boston Scientific is being referred to more favorably in the news media.
Edwards Lifesciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 1.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.5% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Boston Scientific beats Edwards Lifesciences on 10 of the 19 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
This page (NYSE:EW) was last updated on 1/20/2025 by MarketBeat.com Staff
Free EW Stock Alerts